세계의 당뇨병 치료제·기기 시장 규모는 2024년에 1,198억 6,000만 달러에 달하며, 2033년에는 2,444억 6,000만 달러에 달할 것으로 예측되며, 예측 기간인 2025-2033년의 CAGR은 8.3%로 성장할 전망입니다.
당뇨병 치료제 및 기기는 고혈당을 특징으로 하는 만성 대사성 질환인 당뇨병의 관리, 모니터링 및 조절을 돕기 위해 고안된 의약품 치료 및 의료기기를 말합니다. 이러한 의약품 및 의료기기는 심혈관질환, 신경장애, 신장질환, 망막증 등 당뇨병 관련 합병증 예방에 중요한 역할을 하고 있습니다.
당뇨병 치료제는 인슐린 분비를 촉진하거나 인슐린 감수성을 개선하고 포도당 흡수를 억제하여 혈당 조절을 돕는 약물입니다. 이러한 약제들은 작용기전에 따라 다양한 클래스로 분류됩니다. 당뇨병 치료 기기는 모니터링, 치료 관리, 당뇨병의 효과적인 관리를 돕는 의료 툴 및 기기입니다. 이러한 기기들은 당뇨병 관리의 정확성, 편의성 및 환자 순응도를 향상시킵니다.
당뇨병 치료제 및 기기 시장은 전 세계 당뇨병 유병률 증가와 당뇨병 치료제 및 기기의 발전으로 인해 크게 성장하고 있습니다. 연속 혈당 모니터링 시스템, 인슐린 펌프, 스마트 인슐린 펜의 혁신은 당뇨병 관리를 강화하고 이러한 기기의 채택을 확대하는 데 기여했습니다. 모바일 애플리케이션 및 웨어러블 기술과 같은 디지털 건강 솔루션의 통합은 시장 성장을 더욱 촉진하고 있습니다.
예를 들어 2024년 9월, Senseonics Holdings, Inc.와 Ascensia Diabetes Care는 18세 이상의 제1형 및 2형 당뇨병 환자를 위한 차세대 CGM 시스템 Eversense 365의 미국 식품의약국(FDA) 승인을 획득했습니다. 에버센스 365는 세계 최초의 1년 단위 CGM 시스템으로, 당뇨병 기술 및 관리에 있으며, 중요한 돌파구가 될 것입니다.
촉진요인과 억제요인
당뇨병 유병률 증가
당뇨병 유병률 증가는 당뇨병 치료제 및 기기 시장의 성장을 크게 견인하고 있으며, 예측 기간 중에도 시장을 주도할 것으로 예상됩니다. 전 세계 당뇨병 유병률은 생활습관의 변화, 인구의 고령화, 비만율 증가로 인해 급증하고 있습니다. 이러한 급증은 당뇨병 치료제 및 관리 기기에 대한 수요 증가로 이어지고 있습니다.
예를 들어 국제당뇨병연합에 따르면 2021년에는 5억 3,660만 명의 성인(20-79세)이 당뇨병을 앓고 있습니다. 이 수치는 2030년에는 6억 4,280만 명, 2045년에는 7억 8,370만 명으로 증가할 것으로 예측됩니다. 성인 당뇨병 환자 4명 중 3명 이상이 중저소득 국가에 거주하고 있습니다. 이러한 유병률 증가는 당뇨병 치료제 및 치료 기기의 시급한 필요성을 강조하고 있습니다.
당뇨병이 진행되면 환자는 혈당을 관리하기 위해 정기적인 모니터링과 꾸준한 약수처리가 필요합니다. 이 때문에 SMBG 시스템, 지속형 혈당 모니터와 같은 혈당 모니터링 기기, 인슐린 펌프, 펜과 같은 인슐린 전달 기기, 당뇨병 치료제 인슐린, 경구용 혈당 강하제 등 더 나은 당뇨병 관리를 위한 수요가 증가하고 있습니다. 수요 증가와 더불어 시장 기업은 끊임없이 혁신에 초점을 맞추고 수요를 충족시키는 제품을 출시하고 있습니다.
예를 들어 2024년 8월 Insulet Corporation은 혁신적인 Omnipod 5 Automated Insulin Delivery System(Omnipod 5)을 미국에서 2형 당뇨병 환자(18세 이상)에게 사용할 수 있도록 승인했습니다.
또한 아스트라제네카는 2024년 6월 미국 식품의약국(FDA)으로부터 10세 이상 소아 2형 당뇨병(T2D) 환자의 혈당 조절을 개선하기 위한 팔uxiga(성분명: 다파글리플로진)에 대한 승인을 획득했습니다. 기반하고 있습니다. 팔uxiga는 미국에서 성인 T2D 환자를 대상으로 식이요법 및 운동요법의 보조제로 혈당 조절을 개선하는 약물로 승인되었습니다.
고가의 당뇨병 치료 장비
지속혈당측정기(CGM)나 인슐린 펌프와 같은 첨단 당뇨병 치료 기기는 기기 자체의 초기 비용을 제외하고도 센서와 유지보수 비용으로 인해 고가의 비용이 발생할 수 있습니다. 이러한 고비용은 특히 이러한 첨단 기술이 접근하기 어려운 개발도상국에서의 보급을 제한하고 있습니다.
예를 들어 국립보건원에 따르면 CGM의 비용은 12개월 추적관찰 기간 중 평균 4,431달러인 반면, 혈당 모니터는 319달러로 장비 비용을 더하면 CGM의 비용이 크게 상쇄됩니다. 또한 Dexcom G6 송신기는 90일 동안 지속되는 기기 1개에 보험 없이 366달러이며, Dexcom G6 CGM 시스템은 비스마트폰 사용자를 위한 수신기(540달러)와 호환되는 휴대폰을 제외하면 연간 약 8,000달러의 자기부담이 발생합니다.
The global diabetes care drugs & devices market reached US$ 119.86 billion in 2024 and is expected to reach US$ 244.46 billion by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033.
Diabetes care drugs & devices refer to the pharmaceutical treatments and medical devices designed to help manage, monitor and control diabetes, a chronic metabolic disorder characterized by high blood glucose levels. These drugs and devices play a crucial role in preventing diabetes-related complications such as cardiovascular diseases, neuropathy, nephropathy and retinopathy.
Diabetes care drugs are medications that help regulate blood sugar levels by enhancing insulin production, improving insulin sensitivity, or reducing glucose absorption. These drugs are categorized into various classes based on their mechanism of action. Diabetes care devices are medical tools and equipment that assist in monitoring, administering treatments, and managing diabetes effectively. These devices improve accuracy, convenience, and patient compliance in diabetes management.
The diabetes care drugs and devices market is experiencing significant growth, driven by the increasing prevalence of diabetes worldwide and advancements in diabetes care drugs and devices. Innovations in continuous glucose monitoring systems, insulin pumps, and smart insulin pens have enhanced diabetes management, leading to increased adoption of these devices. Integrating digital health solutions, such as mobile applications and wearable technology, has further propelled market growth.
For instance, in September 2024, Senseonics Holdings, Inc. and Ascensia Diabetes Care received the U.S. Food and Drug Administration (FDA) clearance for the next-generation Eversense 365 CGM system for people with Type 1 and Type 2 diabetes aged 18 years and older. Eversense 365 is the world's first One-year CGM system, representing a significant breakthrough in diabetes technology and management.
Market Dynamics: Drivers & Restraints
Rising prevalence of diabetes
The rising prevalence of diabetes is significantly driving the growth of the diabetes care drugs and devices market and is expected to continue driving the market over the forecast period. The global prevalence of diabetes is rising sharply due to lifestyle changes, aging populations, and rising obesity rates. This surge in cases creates a higher demand for diabetes drugs and care devices.
For instance, according to the International Diabetes Federation, in 2021, 536.6 million adults (20-79 years) are living with diabetes i.e., 1 in 10 people. This number is predicted to rise to 642.8 million by 2030 and 783.7 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. This escalating prevalence highlights the urgent need for diabetes care drugs and devices.
As diabetes progresses, patients require regular monitoring and consistent medication to manage their blood glucose levels. This increases demand for blood glucose monitoring devices such as SMBG systems, continuous glucose monitors, insulin delivery devices such as insulin pumps, pens and diabetes drugs insulin, oral hypoglycemics for better diabetes management. In addition to the rising demand, market players are constantly focused on innovations and launching products that meet the demand.
For instance, in August 2024, Insulet Corporation cleared that its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it the first and only AID system FDA-cleared for both type 1 and type 2 diabetes management.
Additionally, in June 2024, AstraZeneca cleared the US Food and Drug Administration (FDA) approval for Farxiga (dapagliflozin) to improve glycaemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older. The FDA approval was based on positive results from the pediatric T2NOW Phase III trial. Farxiga was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycaemic control.
High cost of diabetes care devices
Advanced diabetes care devices such as continuous glucose monitors (CGMs) and insulin pumps can cost anywhere high for sensors and maintenance, not including the upfront costs of the devices themselves. Such high costs limit their adoption, especially in developing regions where these advanced technologies are considered unaffordable.
For instance, according to the National Institute of Health, the costs of CGM are substantially offset if device costs are added, with an average of $4,431 during the 12-month follow-up versus $319 for blood glucose monitor. Additionally, a Dexcom G6 transmitter costs $366 without insurance for one device that lasts 90 days. The Dexcom G6 CGM system can cost around $8,000 annually out-of-pocket, excluding a receiver for non-smartphone users ($540) and a compatible phone.
The global diabetes care drugs & devices market is segmented based on product type, application, end-user and region.
The diabetes devices in the product type segment are expected to be the fastest growing segment of diabetes care drugs & devices market
The demand for blood glucose monitoring devices including both self-monitoring blood glucose (SMBG) systems and continuous glucose monitoring (CGM) systems has significantly increased as patients and healthcare providers seek better, more accurate ways to manage diabetes. Thus, rising demand drives the market players to launch advanced devices. For instance, in August 2024, Medtronic plc cleared the U.S. Food and Drug Administration (FDA) approval for its Simplera continuous glucose monitor (CGM). The discreet design simplifies the insertion and wear experience, eliminating the need for overtape.
Insulin pumps and insulin pens are widely used to manage insulin-dependent diabetes, particularly for Type 1 diabetes patients. Insulin pens, more affordable and portable than pumps, have become essential for diabetes management, leading to steady growth in their adoption. Thus, major and emerging players are focussing on the development of advanced insulin pumps. For instance, in September 2024, Modular Medical, Inc. received U. S. Food and Drug Administration clearance to market and sell its MODD1 pump in the United States.
The integration of technology into diabetes care devices has made the market players develop more user-friendly and efficient devices, increasing their market dominance. For instance, in October 2024, Ascensia Diabetes Care launched the Eversense 365 continuous glucose monitoring (CGM) system, the world's only One Year CGM, for people with diabetes in the U.S. Developed by Senseonics Holdings, Inc., Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal disruptions, enabling confident decisions, long-term peace of mind, and enhanced quality of life with just one CGM.
North America is expected to hold a significant position in the diabetes care drugs & devices market with highest market share
North America, especially the United States, has one of the highest diabetes rates globally, significantly driving the demand for diabetes care products. For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S., approximately 38.4 million people of all ages (about 11.6% of the population) have diabetes. This high prevalence fuels both the demand for diabetes drugs such as insulin and oral medications and advanced monitoring and delivery devices such as CGMs and insulin pumps.
North America particularly the United States and Canada is home to some of the major leading companies in the diabetes care market, including Medtronic, Abbott Laboratories, Dexcom, Roche, Merck & Co., Inc. and Novo Nordisk. These companies significantly influence market trends by innovative product launches, drive innovations and contribute to the availability and distribution of cutting-edge diabetes care drugs and devices.
For instance, in June 2024, Abbott's world-leading FreeStyle Libre portfolio of continuous glucose monitors has revolutionized the way roughly 6 million people worldwide manage their diabetes. The FDA also cleared Libre Rio, Abbott's first over-the-counter CGM system for people with diabetes in the United States. Libre Rio is designed for people ages 18 years and older with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.
Asia-Pacific is growing at the fastest pace in the diabetes care drugs & devices market
The Asia-Pacific region is witnessing a significant rise in diabetes cases due to changing lifestyles, urbanization and an aging population. For instance, the International Diabetes Federation (IDF) reports that by 2045, over 200 million people in the APAC region are projected to have diabetes, making it the region with the highest number of diabetes cases globally. Countries like China, India, Japan and Indonesia are experiencing rapid increases in diabetes prevalence due to urbanization and growing health risk factors like obesity and sedentary lifestyles.
As the number of diabetic patients rises, the demand for both diabetes care drugs and diabetes devices is expanding along with advancements in diabetes care devices and drugs, which helps market players to develop advanced drugs and devices. For instance, in April 2024, Sanofi India Limited launched a new diabetes drug Soliqua after receiving marketing authorization from the Central Drugs Standard Control Organisation (CDSCO), indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise.
Additionally, in November 2024, Beurer India Pvt. Ltd. officially launched the GL 22 Blood Glucose Monitor. The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs. The device features comprehensive monitoring capabilities, including average readings for 7, 14, 30 and 90 days, offering crucial insights into blood glucose trends. These features closely align with HbA1c levels, a critical marker for long-term blood sugar control, ensuring users and healthcare providers can manage diabetes more effectively.
The major global players in the diabetes care drugs & devices market include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Medtronic plc, Terumo Corporation, B. Braun SE, Merck & Co., Inc., Novo Nordisk A/S., Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Insulet Corporation and among others.
The global diabetes care drugs & devices market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
LIST NOT EXHAUSTIVE